Für alle Anleger, die spannende Meinungen und Fakten austauschen möchten!
 |
| |
Ihre verpassten Browser Pushes der letzten 24 Stunden:
Top-News
Der Thementhread zu BioVaxys Technology
Beiträge: 3.075
Zugriffe: 494.599 / Heute: 248
Zugriffe: 494.599 / Heute: 248
|
| 3.049 Beiträge ausgeblendet. |
|
kündigt der Kapitän ja schon das nahende Ende an.
Eine Roadmap ist nicht mehr erkennbar.
Keinerlei Faktenlage.
Absolut kein Investoren-Vertrauen mehr.
Kein Kapital mehr in der Firma.
Ich muß zugeben, dass ich zu optimistisch war.
Olt und der Esel haben wohl Recht gehabt...
So sieht es aktuell aus -> Aber -> das passt alles nicht zusammen!
Die Umsätze sind gering und es gibt keinerlei Verkaufsdruck.
Es könnte auch das finale "Auskotzen" sein, bevor die Gegenbewegung einsetzt.
Ich bleibe auf alle Fälle investiert. Das Geld habe ich eh abgeschrieben, also was solls...
Keinerlei Faktenlage.
Absolut kein Investoren-Vertrauen mehr.
Kein Kapital mehr in der Firma.
Ich muß zugeben, dass ich zu optimistisch war.
Olt und der Esel haben wohl Recht gehabt...
So sieht es aktuell aus -> Aber -> das passt alles nicht zusammen!
Die Umsätze sind gering und es gibt keinerlei Verkaufsdruck.
Es könnte auch das finale "Auskotzen" sein, bevor die Gegenbewegung einsetzt.
Ich bleibe auf alle Fälle investiert. Das Geld habe ich eh abgeschrieben, also was solls...
twitter.com/biovaxys/status/1630686852494630914?s=46
Also ich gehe nicht von einem Totalverlust aus.
Ich gehe aber davon aus, dass es lange dauern wird, bis sich der Nebel hier gelegt hat.
Schlechtes Marketing und Überschätzung der eigenen Fähigkeiten, haben zu dieser Situation geführt.
Die Jungs werden daraus lernen, allerdings ist bei diesem Preis auch jegliche - private - Platzierung einfach viel zu teuer und würde den Wert des Unternehmens weiter verdünnen.
Man muss die Situation schon als ernst bezeichnen - ohne Kapital...
Ich gehe davon aus, dass Papilocare ebenfalls kritisch zu sehen ist (kein Kapital).
Es bleibt wohl nur der Eierstock Krebs Impfstoff übrig.
Ich gehe aber davon aus, dass es lange dauern wird, bis sich der Nebel hier gelegt hat.
Schlechtes Marketing und Überschätzung der eigenen Fähigkeiten, haben zu dieser Situation geführt.
Die Jungs werden daraus lernen, allerdings ist bei diesem Preis auch jegliche - private - Platzierung einfach viel zu teuer und würde den Wert des Unternehmens weiter verdünnen.
Man muss die Situation schon als ernst bezeichnen - ohne Kapital...
Ich gehe davon aus, dass Papilocare ebenfalls kritisch zu sehen ist (kein Kapital).
Es bleibt wohl nur der Eierstock Krebs Impfstoff übrig.
03.03.2023
BioVaxys Technology Corp. reported earnings results for the full year ended October 31, 2022. For the full year, the company reported net loss was CAD 11.73 million compared to CAD 6.46 million a year ago.
Basic loss per share from continuing operations was CAD 0.12 compared to CAD 0.08 a year ago.
BioVaxys Technology Corp. reported earnings results for the full year ended October 31, 2022. For the full year, the company reported net loss was CAD 11.73 million compared to CAD 6.46 million a year ago.
Basic loss per share from continuing operations was CAD 0.12 compared to CAD 0.08 a year ago.
ist die Entwicklung dynamisch negativ.
Wie sollte es ohne Umsätze auch anders aussehen...
Das ist ein typisches Bild einer hoch riskanten StartUp Aktie, egal ob in den USA, Kanade oder hier bei uns.
Die Frage wird nur sein, wie wird sich die finanzielle Situation hier bessern?
NUR duch Umsätze!
Aber dafür fehlt noch die Freigabe der FDA -> für Papilocare.
Womit wollen die Jungs das dann bei Procare aber bezahlen (Einkauf)?
Im best case in Kommission, im worst case in Vorauskasse...
Und was wird mit der Markteinführung von Papilocare in den USA, falls die FDA mitspielt? Das kostet Millionen...
Ich gebe zu, ich brauche zur Zeit erhebliche Phantasie für das Unternehmen, was mir aber echt schwer fällt...
Wie sollte es ohne Umsätze auch anders aussehen...
Das ist ein typisches Bild einer hoch riskanten StartUp Aktie, egal ob in den USA, Kanade oder hier bei uns.
Die Frage wird nur sein, wie wird sich die finanzielle Situation hier bessern?
NUR duch Umsätze!
Aber dafür fehlt noch die Freigabe der FDA -> für Papilocare.
Womit wollen die Jungs das dann bei Procare aber bezahlen (Einkauf)?
Im best case in Kommission, im worst case in Vorauskasse...
Und was wird mit der Markteinführung von Papilocare in den USA, falls die FDA mitspielt? Das kostet Millionen...
Ich gebe zu, ich brauche zur Zeit erhebliche Phantasie für das Unternehmen, was mir aber echt schwer fällt...
Ein kleines Lebenszeichen über Twitter…
twitter.com/biovaxys/status/...fd1zADYytPbMDDRoFA27Q&s=19
twitter.com/biovaxys/status/...fd1zADYytPbMDDRoFA27Q&s=19
www.finanznachrichten.de/...esst-privatplatzierung-ab-007.htm
VANCOUVER, BC, March 16, 2023 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") today announced that it has acquired TAETSoftware Corp ("TAETCo"), a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker ("TAET") technology platform, a proprietary software application which will enable clinical study subjects to record and submit clinical trial Adverse Drug Events ("ADE") reports to study sponsors in real time. In exchange for all of the issued and outstanding shares of TAETCo, the company issued the TAETCo shareholders 24,500,000 common shares, with an additional 2,500,000 common shares payable upon the successful testing of the beta version of the application.
Trial Adverse Events Tracker ("TAET") is an innovative software application designed to enhance and improve tracking of adverse events and/or side effects of subjects enrolled in clinical studies. TAET provides a secure and private link for study subjects to instantly update investigators with adverse events they are experiencing onto an online database for real-time evaluation by study investigators. With customizable fields for ADE's, study subject demographics and disease data, and other study-related variables, TAET provides a high degree of data recording flexibility with the inherent benefit of real-time data submission, and the ability for study subjects and investigators to direct message each other if necessary.
Paper-based reporting has long been the primary method for recording ADEs, but can be limited by under-reporting, poorly documented reporting, and reporting delays. As a web-based or mobile app for reporting ADEs, TAET offers added value compared to conventional reporting tools.1 Furthermore, BioVaxys intends to explore the potential of offering blinded demographic and disease data to companies with an interest in healthcare analytics and data mining.
James Passin, BioVaxys CEO, stated, "The acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting our core business in cancer and viral vaccine development. In addition to providing a fee-based product for recording clinical study ADE's for CROs and study sponsors, BioVaxys will seek to leverage recent breakthroughs in artificial intelligence by collaborating with one or more players in healthcare data mining to develop insights into correlations between demographics and other factors and ADEs."
Jay Dhaliwal, the Founder and CEO of TAETCo and developer of the TAET application, is a registered pharmacist with capital markets experience. He holds a Bachelor of Pharmacy from the University of British Columbia, a Bachelor of Science in Biology from the University of Victoria. Mr. Dhaliwal has agreed to act as consultant to BioVaxys to assist with the commercial development of TAET.
In addition, BioVaxys is pleased to announce that it has also closed a private placement consisting of 5,360,000 common shares at a price of $0.125 per share for gross proceeds of $670,000. All common shares issued pursuant to the private placement will be subject to a statutory hold period of four months and one day. The Company intends to use the proceeds for the private placement of working capital.
1) Fukushima, A., Iessa, N., Balakrishnan, M.R. et al. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience. BMC Med Inform Decis Mak 22, 118 (2022).
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
Trial Adverse Events Tracker ("TAET") is an innovative software application designed to enhance and improve tracking of adverse events and/or side effects of subjects enrolled in clinical studies. TAET provides a secure and private link for study subjects to instantly update investigators with adverse events they are experiencing onto an online database for real-time evaluation by study investigators. With customizable fields for ADE's, study subject demographics and disease data, and other study-related variables, TAET provides a high degree of data recording flexibility with the inherent benefit of real-time data submission, and the ability for study subjects and investigators to direct message each other if necessary.
Paper-based reporting has long been the primary method for recording ADEs, but can be limited by under-reporting, poorly documented reporting, and reporting delays. As a web-based or mobile app for reporting ADEs, TAET offers added value compared to conventional reporting tools.1 Furthermore, BioVaxys intends to explore the potential of offering blinded demographic and disease data to companies with an interest in healthcare analytics and data mining.
James Passin, BioVaxys CEO, stated, "The acquisition of TAETCO provides BioVaxys with a third low-risk near-term revenue generating product, supporting our core business in cancer and viral vaccine development. In addition to providing a fee-based product for recording clinical study ADE's for CROs and study sponsors, BioVaxys will seek to leverage recent breakthroughs in artificial intelligence by collaborating with one or more players in healthcare data mining to develop insights into correlations between demographics and other factors and ADEs."
Jay Dhaliwal, the Founder and CEO of TAETCo and developer of the TAET application, is a registered pharmacist with capital markets experience. He holds a Bachelor of Pharmacy from the University of British Columbia, a Bachelor of Science in Biology from the University of Victoria. Mr. Dhaliwal has agreed to act as consultant to BioVaxys to assist with the commercial development of TAET.
In addition, BioVaxys is pleased to announce that it has also closed a private placement consisting of 5,360,000 common shares at a price of $0.125 per share for gross proceeds of $670,000. All common shares issued pursuant to the private placement will be subject to a statutory hold period of four months and one day. The Company intends to use the proceeds for the private placement of working capital.
1) Fukushima, A., Iessa, N., Balakrishnan, M.R. et al. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience. BMC Med Inform Decis Mak 22, 118 (2022).
About BioVaxys Technology Corp.
Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The Company is advancing vaccines for SARS-CoV-2, SARS-CoV-1, and a pan-sarbecovirus vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. Also in development is CoviDTH®, a diagnostic for evaluating the presence or absence of a T cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
... so gerne geschrieben, dass es die für mich bislang beste Biovaxys-News ist, weil es endlich mal Hand und Fuß hat ... um dann festzustellen, dass "TAET" selbst bislang weder Hand noch Fuß hat ... und man sich da anscheinend nicht mal einig ist, ob man nun der Events oder Event Tracker ist.
Zumindest ist die Homepage bislang ungefähr auf dem Niveau von Biovaxys. Lauter Link-Platzhalter.
Was an der News immerhin gut ist: Man scheint den Laden auf Teufel komm raus nicht untergehen lassen zu wollen. Großer Pluspunkt!
Zumindest ist die Homepage bislang ungefähr auf dem Niveau von Biovaxys. Lauter Link-Platzhalter.
Was an der News immerhin gut ist: Man scheint den Laden auf Teufel komm raus nicht untergehen lassen zu wollen. Großer Pluspunkt!
glauben nach wie vor an den Erfolg. Ken hat geschrieben und seine Zuversicht deutlich gemacht. In der Kommunikation und Darstellung dürfen Biovaxys noch dazulernen. Das Produkt sollte es Erfolg haben ist dann für alle die noch dabei sind ein großer Lichtblick.
Hast du bitte ein Link zur Homepage?
Danke
Zumindest ist die Homepage bislang ungefähr auf dem Niveau von Biovaxys.
Danke
Zumindest ist die Homepage bislang ungefähr auf dem Niveau von Biovaxys.
Solche Übernahmen sehen nach dem letzten Strohhalm aus. Es wird mit Aktien bezahlt, was unsere Investition weiter verwässert.
Und der Erfolg einer App, im Riesen Teich an Apps, kann als ziemlich Risikobehaftet angesehen werden.
Meine Meinung ist da nicht sehr optimistisch. Schuster bleib bei Deinen Leisten…
Mir wären gute Nachrichten aus Lyon lieber!
Und der Erfolg einer App, im Riesen Teich an Apps, kann als ziemlich Risikobehaftet angesehen werden.
Meine Meinung ist da nicht sehr optimistisch. Schuster bleib bei Deinen Leisten…
Mir wären gute Nachrichten aus Lyon lieber!
Explanation of IP Valuation in 2022 Audit
Many of you have had questions regarding the write-down of the intellectual property (“IP”) assets in BioVaxys’ 2022 annual audit. Across the industry, auditors of public companies have indicated that there is currently considerable additional scrutiny from the public company auditing regulatory boards (CPAB in Canada and PCAOB in the US) on the work done to substantiate management estimates. This type of write-down, which we understand has become commonplace and impacted many other Canadian companies, is partially due to Canadian Audit Standard 540 – Auditing Accounting Estimates and Related Disclosures. This standard, coupled with CPAB’s enhanced requirements, have auditors in a position where valuations must be audited extensively. This means auditors must be able to test and verify all estimate inputs, which is difficult in the absence of current cash flows or purchase agreements related to imminent sales.
Thank you.
-BioVaxys
Many of you have had questions regarding the write-down of the intellectual property (“IP”) assets in BioVaxys’ 2022 annual audit. Across the industry, auditors of public companies have indicated that there is currently considerable additional scrutiny from the public company auditing regulatory boards (CPAB in Canada and PCAOB in the US) on the work done to substantiate management estimates. This type of write-down, which we understand has become commonplace and impacted many other Canadian companies, is partially due to Canadian Audit Standard 540 – Auditing Accounting Estimates and Related Disclosures. This standard, coupled with CPAB’s enhanced requirements, have auditors in a position where valuations must be audited extensively. This means auditors must be able to test and verify all estimate inputs, which is difficult in the absence of current cash flows or purchase agreements related to imminent sales.
Thank you.
-BioVaxys
Überhaupt einen bilanzierbaren Wert auf sein geistiges Eigentum in der Bilanz auszuweisen -> um es dann abschreiben zu können???
Meine Patente sind 1 mio wert -> ok dann schreibe ich jedes Jahr 200 K einfach ab über 5 Jahre ;-)
Das klingt wie der ultimative Steuertrick ;-)
In Deutschland ist so etwas sicherlich nicht erlaubt oder?
Meine Patente sind 1 mio wert -> ok dann schreibe ich jedes Jahr 200 K einfach ab über 5 Jahre ;-)
Das klingt wie der ultimative Steuertrick ;-)
In Deutschland ist so etwas sicherlich nicht erlaubt oder?
Da steht noch kein cent Umsatz dagegen, der diesen Werte in irgend einer Form stützen könnte.
Alles reine Annahme...
Alles reine Annahme...
In case you did not see this posted earlier today on Twitter, BioVaxys and partner ProCare Health will be attending the 35th International Papillomavirus Society (IPVC) meeting in Washington DC from April 17-21 2023 where we will attend scientific symposia on developments in HPV---and most importantly---meet US Opinion Leaders to raise awareness of Papilocare ahead of our planned US distribution.
A total of six (6) scientific abstracts on new Papilocare clinical studies have been accepted for presentation at IPVC:
EFECT OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN A HPV18 PREGNANT WOMAN WITH CIN II/III LESIONS
EFFECTIVENESS OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV PATIENTS IN OVER 35- OR 40-YEAR OLD SUBGROUPS
EFFECT OF A CORIOLUS VERSICOLOR-BASED VAGINAL GEL FOR HIGH-RISK HPV CLEARANCE AND CYTO-NORMALIZATION IN A 44-YEAR-OLD PATIENT WITH HR-HPV PERSITENCE OF MORE THAN 10 YEARS
EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV INFECTED PATIENTS: RESULTS OF 6 DIFFERENT STUDIES
EFFECTIVENESS OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HPV AND HIV PATIENTS: A PILOT OBSERVATIONAL STUDY
EFFECT OF A CONSERVATIVE MANAGEMENT OF CIN II USING A CORIOLUS VERSICOLOR-BASED VAGINAL GEL: AN OBSERVATIONAL STUDY
IPVC is a major international scientific meeting with extensive exposure among clinicians, and BioVaxys is excited to be here supporting Papilocare.
Thank you!
-The BioVaxys Team
A total of six (6) scientific abstracts on new Papilocare clinical studies have been accepted for presentation at IPVC:
EFECT OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN A HPV18 PREGNANT WOMAN WITH CIN II/III LESIONS
EFFECTIVENESS OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV PATIENTS IN OVER 35- OR 40-YEAR OLD SUBGROUPS
EFFECT OF A CORIOLUS VERSICOLOR-BASED VAGINAL GEL FOR HIGH-RISK HPV CLEARANCE AND CYTO-NORMALIZATION IN A 44-YEAR-OLD PATIENT WITH HR-HPV PERSITENCE OF MORE THAN 10 YEARS
EFFICACY OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HIGH-RISK HPV INFECTED PATIENTS: RESULTS OF 6 DIFFERENT STUDIES
EFFECTIVENESS OF A MULTI-INGREDIENT CORIOLUS VERSICOLOR-BASED VAGINAL GEL IN HPV AND HIV PATIENTS: A PILOT OBSERVATIONAL STUDY
EFFECT OF A CONSERVATIVE MANAGEMENT OF CIN II USING A CORIOLUS VERSICOLOR-BASED VAGINAL GEL: AN OBSERVATIONAL STUDY
IPVC is a major international scientific meeting with extensive exposure among clinicians, and BioVaxys is excited to be here supporting Papilocare.
Thank you!
-The BioVaxys Team
|
Neueste Beiträge aus dem BioVaxys Technology Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 3.074 | Der Thementhread zu BioVaxys Technology | The Sailor | Lalle1895 | 06:17 | ||
| 159 | BioVaxys Technology - Der neue Thementhread 2022 | Der Seemann | The Sailor | 19.03.23 12:13 | ||
| 1 | Kauf | Sandibi | Gueri | 01.04.22 15:49 | ||
| BioVaxys wird bei dieser Veranstaltung am 10. Juni | NAI500 | 09.06.21 03:04 | ||||
| 1.307 | @all | Meister Joda | Frischmeister | 25.04.21 02:22 |
